Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 19/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.76 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.76 |
| ▸ | TDO2 | P48775 | 3/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.76 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22808972 | 1.00 | IDO1 (0.76) | IDO1CYP2C9CYP2C8TDO2CYP3A4 | |
| SCHEMBL17740979 | 1.00 | IDO1 (0.76) | IDO1CYP2C9CYP2C8TDO2CYP3A4 | |
| SCHEMBL18806738 | 1.00 | IDO1 (0.76) | IDO1CYP2C9CYP2C8TDO2CYP3A4 | |
| SCHEMBL17729171 | 1.00 | IDO1 (0.76) | IDO1CYP2C9CYP2C8TDO2CYP3A4 | |
| SCHEMBL17741033 | 1.00 | IDO1 (0.76) | IDO1CYP2C9CYP2C8TDO2CYP3A4 | |
| SCHEMBL18806739 | 1.00 | IDO1 (0.76) | IDO1CYP2C9CYP2C8TDO2CYP3A4 | |
| SCHEMBL17741008 | 1.00 | IDO1 (0.76) | IDO1CYP2C9CYP2C8TDO2CYP3A4 | |
| SCHEMBL22808960 | 1.00 | IDO1 (0.76) | IDO1CYP2C9CYP2C8TDO2CYP3A4 | |
| SCHEMBL23680421 | 0.91 | IDO1 (0.63) | IDO1CYP2C9CYP2C8TDO2CYP3A4 | |
| SCHEMBL20621686 | 0.90 | IDO1 (0.73) | IDO1CYP2C9CYP2C8TDO2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197973-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2017-07-13 | — | — | US | claimed |
| US-9643972-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2017-05-09 | — | — | US | claimed |
| EP-3854394-A1 | IMMUNOREGULATORY AGENTS | Flexus Biosciences, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3215153-B1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3215153-B1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20190002472-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190002472-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2019-01-03 | — | — | US | disclosed |
| US-10106546-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180282281-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2018-10-04 | — | — | US | disclosed |
| US-20170197973-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197973-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2017-07-13 | — | — | US | disclosed |
| US-9643972-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643972-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160137652-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160137652-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. | 2016-05-19 | — | — | US | disclosed |
| WO-2016073770-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES, INC. (US) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106546-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2655/4885CYP2C8 1154/4885 |
| US-20180282281-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2655/4885CYP2C8 1154/4885 |
| US-20160137652-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2655/4885CYP2C8 1154/4885 |
| US-20190002472-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2655/4885CYP2C8 1154/4885 |
| US-20170197973-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | IDO1 1/4885CYP2C9 2655/4885CYP2C8 1154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.